JP2023522055A5 - - Google Patents
Info
- Publication number
- JP2023522055A5 JP2023522055A5 JP2022562977A JP2022562977A JP2023522055A5 JP 2023522055 A5 JP2023522055 A5 JP 2023522055A5 JP 2022562977 A JP2022562977 A JP 2022562977A JP 2022562977 A JP2022562977 A JP 2022562977A JP 2023522055 A5 JP2023522055 A5 JP 2023522055A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011048P | 2020-04-16 | 2020-04-16 | |
| US63/011,048 | 2020-04-16 | ||
| US202063092072P | 2020-10-15 | 2020-10-15 | |
| US63/092,072 | 2020-10-15 | ||
| IBPCT/IB2021/000021 | 2021-01-07 | ||
| PCT/IB2021/000021 WO2021209808A1 (en) | 2020-04-16 | 2021-01-07 | Cer-001 therapy for treating kidney disease |
| PCT/IB2021/000282 WO2021209822A1 (en) | 2020-04-16 | 2021-04-15 | Cer-001 therapy for treating kidney disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522055A JP2023522055A (ja) | 2023-05-26 |
| JP2023522055A5 true JP2023522055A5 (https=) | 2024-04-23 |
| JPWO2021209822A5 JPWO2021209822A5 (https=) | 2024-04-23 |
Family
ID=76034906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562977A Pending JP2023522055A (ja) | 2020-04-16 | 2021-04-15 | 腎臓病を治療するためのｃｅｒ－００１療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11752163B2 (https=) |
| EP (1) | EP4135838A1 (https=) |
| JP (1) | JP2023522055A (https=) |
| KR (1) | KR20230004606A (https=) |
| CN (1) | CN115666720A (https=) |
| AU (1) | AU2021254856A1 (https=) |
| CA (1) | CA3177735A1 (https=) |
| IL (1) | IL297046A (https=) |
| MX (1) | MX2022012906A (https=) |
| WO (1) | WO2021209822A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2984286T3 (es) * | 2017-08-10 | 2024-10-29 | Abionyx Pharma Sa | Apómeros |
| IL297046A (en) | 2020-04-16 | 2022-12-01 | Abionyx Pharma Sa | Treatment of kidney disease using cer-001 |
| KR20240018430A (ko) * | 2021-04-15 | 2024-02-13 | 아비오닉스 파마 에스에이 | 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용 |
| CA3247588A1 (en) * | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES |
| JP2025519606A (ja) * | 2022-06-10 | 2025-06-26 | アビオニクス ファーマ エスエー | 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法 |
| WO2023237927A2 (en) * | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932536A (en) | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| EP1545576A2 (en) | 2002-07-30 | 2005-06-29 | Esperion Therapeutics Inc. | Methods of using non-human animal apoliprotein a-i protein |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| LT2939683T (lt) * | 2009-02-16 | 2017-03-27 | Cerenis Therapeutics Holding Sa | Apolipoproteino a-i mimetikai |
| EP2673296B1 (en) | 2011-02-07 | 2018-10-24 | Cerenis Therapeutics Holding SA | Lipoprotein complexes and manufacturing and uses thereof |
| AU2012236889A1 (en) | 2011-03-25 | 2013-05-09 | The Trustees Of Columbia University In The City Of New York | Pegylated human HDL particle and process for production thereof |
| US9938312B2 (en) | 2011-03-25 | 2018-04-10 | University Of Georgia Research Foundation, Inc. | Compounds and methods for chemical and chemo-enzymatic synthesis of complex glycans |
| JP6438417B2 (ja) | 2013-03-15 | 2018-12-12 | セレニス セラピューティクス ホールディング エスアー | スフィンゴミエリンおよびジヒドロスフィンゴミエリンの合成のための方法 |
| EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| WO2015173633A2 (en) * | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| WO2016085986A1 (en) | 2014-11-24 | 2016-06-02 | Northwestern University | High density lipoprptein nanoparticles for inflammation |
| WO2018022511A1 (en) * | 2016-07-25 | 2018-02-01 | The Trustees Of The University Of Pennsylvania | Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof |
| EP3490579B1 (en) * | 2016-07-27 | 2025-09-10 | Hartis-Pharma SA | Therapeutic combinations to treat red blood cell disorders |
| WO2018029505A1 (en) * | 2016-08-11 | 2018-02-15 | Cerenis Therapeutics Holding Sa | Cer-001 therapy for treating familial primary hypoalphalipoproteinemia |
| FR3100715B1 (fr) | 2019-09-12 | 2023-09-29 | Francais Du Sang Ets | Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte |
| IL297046A (en) | 2020-04-16 | 2022-12-01 | Abionyx Pharma Sa | Treatment of kidney disease using cer-001 |
| KR20230004605A (ko) | 2020-04-16 | 2023-01-06 | 아비오닉스 파마 에스에이 | 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법 |
| WO2021209808A1 (en) | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Cer-001 therapy for treating kidney disease |
-
2021
- 2021-04-15 IL IL297046A patent/IL297046A/en unknown
- 2021-04-15 US US17/231,659 patent/US11752163B2/en active Active
- 2021-04-15 WO PCT/IB2021/000282 patent/WO2021209822A1/en not_active Ceased
- 2021-04-15 EP EP21726966.1A patent/EP4135838A1/en active Pending
- 2021-04-15 JP JP2022562977A patent/JP2023522055A/ja active Pending
- 2021-04-15 CA CA3177735A patent/CA3177735A1/en active Pending
- 2021-04-15 KR KR1020227039570A patent/KR20230004606A/ko active Pending
- 2021-04-15 CN CN202180035372.6A patent/CN115666720A/zh active Pending
- 2021-04-15 AU AU2021254856A patent/AU2021254856A1/en active Pending
- 2021-04-15 MX MX2022012906A patent/MX2022012906A/es unknown
-
2023
- 2023-07-21 US US18/356,280 patent/US12364705B2/en active Active
-
2025
- 2025-06-18 US US19/242,564 patent/US20250312366A1/en active Pending